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MULTIPLE-FIELD INTERSTITIAL PHOTODYNAMIC THERAPY 
OF SUBCUTANEOUSLY TRANSPLANTED CHOLANGIOCELLULAR 
CARCINOMA RS-1 IN RATS
D.A. Tzerkovsky*
N.N. Alexandrov National Cancer Center of Belarus, Lesnoy 223040, Republic of Belarus
The aim of present study was to investigate an antitumor efficacy of multiple-field interstitial photodynamic therapy (iPDT) in vivo. 
Materials and Methods: The study was performed on 15 white random-bred rats with subcutaneously transplanted cholangiocellular 
carcinoma RS-1. Chlorine-based photosensitizer (PS) Ce6CPPPS was administered via single injection at a dose of 2.5 mg/kg into the 
animal’s caudal vein. Photoirradiation (PI) of tumors was carried out 3 h after PS administration using 7 optical fibers SMA-905 with 
diode laser with 660 ± 5 nm wavelength at exposure doses of 150 and 300 J/cm² with 0.21 W/cm² fluency rate. The total power density 
was 360 mW and treatment time was 12 and 24 min. Antitumor efficacy of iPDT was assessed by evaluation of necrosis areas and depth 
of necrosis in experimental tumors. Results: The results have shown that interstitial PI with multi-field low power density enhanced the 
antitumor effect of PDT in the RS-1 model. Necrosis areas in tumor tissues after PI with exposure doses 150 and 300 J/cm2 24 h and 
96 h after treatment were 83.78 ± 4.25 and 100% (p = 0.00074); 56.79 ± 3.24 and 95.46 ± 1.64% (p < 0.00001), respectively. Conclu-
sion: An analysis of the literature data and the results obtained in this study evidence on high effectiveness of the method of multiple-field.
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Photodynamic therapy (PDT) is a modern and highly 
effective option in the treatment of malignant tumors of the 
skin, lung, bladder, brain, pancreas and other localiza-
tions [1–3]. PDT is a treatment method based on the 
significant increase of the cytotoxicity of drugs with photo-
irradiation (PI) of the tumor tissue. According to numerous 
studies, photochemical reactions include a direct interac-
tion of excited molecules with the help of PI, photosensi-
tizer (PS) on the substrate and forming transient radicals 
that react with oxygen. Interaction initiates a complex cas-
cade of free radicals, such as singlet oxygen (1O2), hydroxyl 
radical (OH), hydrogen peroxide (H2O2) and superoxide 
anion radical (O2–), causing the development of oxidative 
stress syndrome. As a result, PDT effectively induces 
tumor-cell apoptosis and necrosis (Necr). The two pos-
sible mechanisms might be: a) promoting mitochondria 
to release cytochrome C and activate caspase-3, then 
to initiate apoptosis; b) destroying microvessels, inhibition 
of angiogenesis and the induction of ische mia and anoxia 
of tumor cells, resulting in ischemic Necr [2, 4, 5].
PDT has rarely been used clinically in the treatment 
of liver tumors, mainly because of effective accumula-
tion of PS in liver tissue [6, 7]. Distribution studies show 
that PS are accumulated in high amounts in reticulo-
endothelial tissue, such as liver, spleen, and kidney, and 
in particular, liver tissue contains high PS levels after 
its administration [8, 9]. Therefore, superficial tumor 
PI causes substantial liver Necr. The limited light penetra-
tion during superficial illumination makes it impossible 
to treat deep-seated or larger solid tumors. In order 
to prevent possible complications, research teams 
recommended the use of an interstitial type of PI of liver 
tumors.
The ability of interstitial photodynamic therapy (iPDT) 
to cause a destruction of liver tumors has been demon-
strated in in vitro [10–12] and in vivo [13–15] studies, using 
hematoporphyrin, photofrin, meta-tetra(hydroxyphenyl)
chlorine (mTHPC) and other photosensitizing agents.
In the present study, we investigated the effects 
of Ce6CPPPS-mediated PDT using multi-field intersti-
tial PI on subcutaneously transplanted cholangiocel-
lular carcinoma RS-1 in rats.
MATERIALS AND METHODS
Experimental animals. The study was con-
ducted on 15 white randomly bred rats of both sexes 
(220 ± 40 g) obtained from the vivarium of N.N. Ale-
xandrov National Cancer Center of Belarus. The animals 
received a standard diet and had permanent access 
to water. All manipulations were carried out according 
to Methodic instructions for carrying out preclinical 
investigations of the pharmacokinetics of pharmaco-
logic substances and drugs presented in the “Good 
Laboratory Practice TKP 125-2008” (Health Ministry 
of Republic Belarus, Minsk). Animal experiments were 
performed according to the Rules of Ethic Commit-
tee. Before treatment, animals were anesthetized 
by intramuscular introduction of a solution of droperidol 
(5.0 mg/kg) and fentanil (0.05 mg/kg).
Experimental tumor model. As experimental 
tumor model, we used rat cholangiocellular carcinoma 
RS-1. RS-1 induced in rats with acetylaminefluorene 
in 1956 was identified as hepatocholangioma and was 
maintained by subcutaneous transplantation [16]. Be-
fore the treatment, the animals were anesthetized and 
immobilized. For experiments, tumor homogenate was 
implanted subcutaneously into the left inguinal area 
by the injection of 0.5 ml of 20% tumor cells suspen-
sion in 0.6% Hank’s solution. The experiments were 
performed 39–40 days after tumor implantation with 
tumor diameter reaching 40–50 mm.
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Photosensitizer. Chlorin e6 conjugated with poly-
vinyl pyrrolidone (Ce6CPPPS) produced by Scientific 
Pharmaceutical Center of RUE “Belmedpreparaty”, 
Minsk, Republic of Belarus) was injected into the tail 
vein at a standard dose of 2.5 mg/kg.
Interstitial photodynamic therapy. PI of tumors was 
carried out 3 h after PS administration using diode laser 
with 660 ± 5 nm wavelength (“PDT Diode laser”, Minsk, 
Republic Belarus) at exposure doses of 150 and 300 J/cm² 
with 0.21 W/cm² fluency rate. The total power density was 
360 mW and treatment time was 12 and 24 min. 7 optical 
fibers SMA-905 (“Fotonika Plus”, Ukraine) for PI were 
introduced into the tumor at a distance of 1 cm from each 
other at a depth of 1–1.5 cm (Fig. 1).
Fig. 1. Multiple-field iPDT: a — photo-irradiation session; b — sub-
cutaneously transplanted tumor during the photo-irradiation session
The distribution of the total power density for each 
fiber is shown in Table 1 and Fig. 2.
Table 1. Distribution of the total power density (P = 360 mW) to optical fibers
Optical fiber No. 1 2 3 4 5 6 7
Power density, mW 43.2 36.0 50.4 99.4 43.2 42.4 45.4
Power density, % 12.0 10.0 14.0 27.6 12.0 11.8 12.6
Antitumor efficacy was evaluated 24 and 96 h after 
the treatment by quantification of RS-1 tumor necrosis 
area (NecrA) by vital staining of tumor bearing animals 
with 0.6% Evans blue solution. The animals were sac-
rificed by chloroform; the tumors were removed, fixed 
in 10% formalin solution and frozen. Transverse tumor 
sections 2–3 mm thick were made. NecrA due to di-
rect effect on tumor cells or structural and functional 
disorders in microcirculation remained unstained. The 
percentage of tumor necrotic unstained parts was 
evaluated using “ImageJ” (NIH, Bethesda, USA).
Statistical processing of the results. The values 
obtained were processed using standard statistical 
methods of Origin Stat 7.0 software. Statistical signifi-
cance of differences was relevant at p < 0.05.
RESULTS
Early post-treatment changes. In the study, the 
sensitivity of subcutaneously implanted RS-1 to iPDT 
was investigated. According to our findings, all animals 
subjected to iPDT at an exposure dose 300 J/cm2 pre-
sented the necrotic changes of maximal size (100%). 
In the control group, this index showing the emergence 
of spontaneous central Necr was insignificant (14.88 ± 
4.33%). Post-treatment necrotic changes after iPDT were 
assessed using the vital staining technique with Evans 
blue. Fig. 3 shows the data on NecrA in histotopographic 
sections of RS-1 in untreated control and 24 h after iPDT 
at the exposure doses of 150 and 300 J/cm2.
Fig. 4 shows the data on NecrA in histotopographic 
sections of RS-1 in untreated control and 96 h after iPDT 
at the exposure doses of 150 and 300 J/cm2.
Percentage of Necr in groups of animals treated with 
iPDT at the exposure doses of 150 and 300 J/cm2 24 and 
96 h after treatment is shown in Table 2.
Depth of tumor Necr in groups of animals treated with 
iPDT at exposure doses of 150 and 300 J/cm2 24 and 
96 h after treatment is shown in Table 3.
Fig. 2. Scheme of fibers location in the tumor and tumor cell 
death mechanism
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Table 3. Depth of Necr in histotopographic sections of subcutaneously 
transplanted RS-1 tumor of rats after treatment
Groups Number of sections, n
Depth of tumor 
Necr# (L), сm Mean NecrA (Sн), %
Control 16 – 14.88 ± 4.33[min = 4.43; maх = 20.25]
iPDT* 150 J/сm2 16 2.69 ± 0.16 83.78 ± 4.25[min = 53.46; maх = 100]
iPDT* 300 J/сm2 14 2.39 ± 0.11 100[min = 100; maх = 100]
iPDT** 150 J/сm2 15 2.15 ± 0.11 56.79 ± 3.24[min = 36.00; maх = 83.63]
iPDT** 300 J/сm2 15 2.84 ± 0.15 95.46 ± 1.64[min = 81.79; maх = 100]
Note: #L iPDT 150 J/сm2 24 h vs L iPDT 150 J/сm2 96 h, p = 0.009; L iPDT 
300 J/сm2 24 h vs L iPDT 300 J/сm2 96 h, p = 0.022.
The results obtained suggest that iPDT with multi-field 
low power density PI enhances the effect on the RS-1 rats 
tumor model. The use of exposure dose of 300 J/cm2 sig-
nificantly increases NecrA in tumor tissues compared with 
150 J/cm2 24 h (p = 0.00074) and 96 h (p < 0.00001).
DISCUSSION
Malignant primary and metastatic liver tumors are 
a serious problem for modern oncology. The main 
treatment for this type of tumors is surgical removal and 
chemotherapy. In spite of obvious achievements of the 
medical science of the last decades, the results of treat-
ment of patients with liver tumors remain disappointing. 
With poor prognosis, development of new therapeutic 
modalities is desirable, especially for patients with non-
resectable, non-transplantable, or recurrent liver tumors. 
Local tumor ablation therapies such as radiofrequency 
ablation, ethanol injection, cryotherapy, and PDT are 
potentially useful palliative approaches. iPDT is an effec-
tive and promising method of treatment of liver tumors.
At the moment, we found only a few articles, confirm-
ing the effectiveness of iPDT in the treatment of primary 
and metastatic liver tumors in laboratory animals [13, 14]. 
Experimental studies, using hematoporphyrin derivative 
and photofrin, have shown iPDT to be capable of inducing 
tumor destruction within the liver, despite limitations like 
non-selective uptake and limited light penetration [13]. 
van Hillegersberg et al. [13] reported about high antitumor 
efficacy of iPDT (λ = 625 nm; 200 mW/cm2; 100–1600 J) 
with intravenously administered photofrin at a dose 
of 5 mg/kg in the treatment of colon carcinoma CC531, 
implanted in liver of Wag/Rij rats. The NecrA in the tumor 
and surrounding normal liver tissues depended on the 
absorbed dose of PI and increased with its increase 
(p < 0.001). The authors noted that application of an ex-
posure dose of 800 J allows to achieve complete regres-
sion of tumors in 66.7% of animals. The authors have 
proved the fact that the use of iPDT allows achieving 
a good therapeutic results with a minimal risk of damage 
to normal liver tissues. Rovers et al. [14] performed iPDT 
(λ = 652 nm, 0.1 W, 15 J) with intravenously administered 
of mTHPC at a dose 0.3 mg/kg of body weight on Wag/Rij 
rats with metastatic liver orthotopic model CC531 colon 
adenocarcinoma. Authors reported that iPDT resulted 
in complete tumor remission in 87% of animals [14].
van Duijnhoven et al. [17] investigated effects of iPDT 
(λ = 652 nm, 200 mW, 16 J/сm2) with mTHPC (0.3 mg/kg) 
on liver metastases of orthotopic model of CC531 colon 
adenocarcinoma. Authors reported that iPDT was effec-
tive in causing photodynamically-induced photochemical 
Necr of tumors, but it did not affect the growth rate of no-
nilluminated tumors in the liver. Immunological staining 
Fig. 3. Histotopographic sections of subcutaneously transplanted rats cholangiocellular carcinoma RS-1 in control group (a); 
24 h after iPDT at the exposure doses of 150 J/cm2 (b) and 300 J/cm2 (c) (blue — viable tumor tissue, red — photochemical Necr)
Table 2. NecrA in histotopographic sections of subcutaneously transplanted RS-1 tumor of rats after treatment
Groups Number of sections, n Mean tumors area# (Sc), сm2 p Mean NecrA& (Sн), % p
Control 16 11.78 ± 1.12[min = 6.33; maх = 14.32] –
14.88 ± 4.33
[min = 4,43; maх = 20,25] –
iPDT* 150 J/сm2 16 13.57 ± 0.94[min = 9.33; maх = 20.81] 0.23
83.78 ± 4.25
[min = 53.46; maх = 100] < 0.00001
iPDT* 300 J/сm2 14 9,74 ± 0,53[min = 5.39; maх = 11.33] 0.11
100
[min = 100; maх = 100] < 0.00001
iPDT** 150 J/сm2 15 9.53 ± 0.71[min = 5.81; maх = 13.61] 0.10
56.79 ± 3.24
[min = 36.00; maх = 83.63] < 0.00001
iPDT** 300 J/сm2 15 13.43 ± 1.32[min = 6.98; maх = 22.39] 0.35
95.46 ± 1.64
[min = 81.79; maх = 100] < 0.00001
Note: Tables 2 and 3: *NecrA in the tumor was evaluated 24 h after iPDT. **NecrA in the tumor was evaluated 96 h after iPDT. #Sc iPDT 150 J/сm2 24 h vs Sc iPDT 
150 J/сm2 96 h, p =0.0018; Sc iPDT 300 J/сm2 24 h vs Sc iPDT 300 J/сm2 96 h, p = 0.0015; Sc iPDT 150 J/сm2 24 h vs Sc iPDT 300 J/сm2 24 h, p = 
0.0013; Sc iPDT 150 J/сm2 96 h vs Sc iPDT 300 J/сm2 96 h, p = 0.015. &Sн iPDT 150 J/сm2 24 h vs Sн iPDT 150 J/сm2 96 h, p = 0.00002; Sн iPDT 
300 J/сm2 24 h vs Sн iPDT 300 J/сm2 96 h, p = 0.01; Sн iPDT 150 J/сm2 24 h vs Sн iPDT 300 J/сm2 24 h, p = 0.00074; Sн iPDT 150 J/сm2 96 h vs Sн iPDT 
300 J/сm2 96 h, p < 0.00001.
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of tumors showed natural killer cells to be significantly 
lower in tumors treated with interstitial PI than in control 
tumors (p < 0.05). Otake et al. [15] published the results 
of their study on the efficacy of iPDT (λ = 630 nm, 160 mW, 
47–90 J/cm2) with 5-ALA at a dose of 500 mg/kg ad-
ministered intravenously 3 h before PI in the treatment 
of chemically induced hepatocellular carcinoma in rats. 
The authors concluded that in all treated tumors, Necr 
was evident at 24 h after 5ALA-iPDT [15]. Several teams 
of scientists made successful attempts for the clinical 
testing of iPDT for patients with unresectable primary and 
metastatic malignant liver tumors [6, 7]. Vogl et al. [7] 
presented the results of several phase I clinical trials based 
on the use of iPDT in the treatment of the liver metastases. 
In the first study authors reported about 5 patients with 
liver metastasis of colorectal cancer treated with PS SQN 
400 (mTHPBC) at a dose of 6 mg/kg and PI (λ = 740 nm; 
60 J/cm2) 120 h after SQN 400 admi nistration. Depending 
on the location and size of lesions, the authors have used 
from 4 to 7 special fibers installed in the tumor site under 
the center CT control. After 3 months in all cases CT study 
recorded photodynamically-induced Necr with no evi-
dence of damage to the normal liver parenchyma, and 
after 6 months in 50% of the metastases continued growth 
was not revealed [7]. In the second study, the authors 
have included 4 patients with liver metastasis of colorectal 
cancer (n = 3) and melanoma (n = 1). PS LS 11 (Talaporfin 
sodium) was injected intravenously at a standard dose 
of 40.0 mg/m2. At 4 h post-injection, a tumor was pho-
toirradiated with a “PDT laser” with 25 mm optical fibers 
(λ = 630 nm; 400 mW/cm2; 100 J/cm2). The average size 
of Necr, confirmed the results of CT studies, was 14 mm. 
At the control observation after 6 weeks in 2 cases com-
plete regression of tumor was recorded [7].
However, a moderate number of studies in this field 
points on the need for further research to determine 
antitumor efficacy of iPDT in the treatment of this pathol-
ogy. In further experimental studies, we plan to study the 
antitumor efficacy of iPDT in the treatment of other tumor 
strains. If positive results will be obtained, we will be able 
to recommend the developed method for approbation 
in clinical oncology.
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Fig. 4. Histotopographic sections of subcutaneously transplanted rats cholangiocellular carcinoma RS-1 in control group (a); 
96 h after iPDT at the exposure doses of 150 J/cm2 (b) and 300 J/cm2 (c) (blue — viable tumor tissue, red — photochemical Necr)
